
- Founded
- 2024
- Employees*
- 4
- Funding to Date*
- $2,830,000
- Website
- www.hexemb.io/
Extending the human health span has long been a visionary goal for humanity, and Hexembio is at the forefront of achieving it. The company is revolutionizing aging and disease prevention by rejuvenating Hematopoietic Stem Cells (HSCs), also known as blood stem cells. This breakthrough offers exciting new possibilities for approaching age-related decline and chronic diseases, a phenomenon directly impacted by aging blood stem cells.
To accelerate its path to market and FDA approval, Hexembio is first targeting bone marrow transplant failure—a life-threatening condition. In preclinical studies, their approach has reduced transplant failure by up to 10 times in mice, offering hope for patients with few other treatment options.
What sets Hexembio apart from existing longevity therapies is the speed, minimal invasiveness, and lasting impact of their treatment. Blood stem cells are extracted from the patient’s bone marrow in a single appointment, rejuvenated in the lab, and then returned intravenously in a second visit. This therapy not only rejuvenates the blood system but benefits multiple organs, including the skin and hair, resulting in both improved function and a visibly younger appearance.The team behind Hexembio includes Gabriel Levesque-Tremblay (PhD), Samira Kiani (MD), Mo Ebrahimkhani (MD), and Joshua Hislop (PhD candidate)—pioneers in stem cell engineering and CRISPR technologies, as well as seasoned entrepreneurs. Their groundbreaking work has been published in Nature and featured in the New York Times. With strong backing from top investors such as Draper Associates, Gaingels, and SOSV, Hexembio is rapidly advancing toward its fundraising goals and transforming the future of human longevity.